Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
The approach of Bayesian mixed effects modeling is an appropriate method for estimating both population-specific as well as subject-specific times to steady state. In addition to pure estimation, the approach allows to determine the time until a certain fraction of individuals of a population has reached steady state with a pre-specified certainty. In this paper a mixed effects model for the parameters of a nonlinear pharmacokinetic model is used within a Bayesian framework. Model fitting by means of Markov Chain Monte Carlo methods as implemented in the Gibbs sampler as well as the extraction of estimates and probability statements of interest are described. Finally, the proposed approach is illustrated by application to trough data from a multiple dose clinical trial.
Jordan
Paul
P
Pharma Development, Clinical Science, F. Hoffmann-La Roche Ltd., Basel, Switzerland. paul.jordan@roche.com
Brunschwig
Hadassa
H
Luedin
Eric
E
D000328:Adult; D001499:Bayes Theorem; D017321:Clinical Trials, Phase I as Topic / Q000706:statistics & numerical data*; D003627:Data Interpretation, Statistical; D006801:Humans; D008297:Male; D008390:Markov Chains; D008875:Middle Aged; D008954:Models, Biological; D015233:Models, Statistical; D009010:Monte Carlo Method; D017711:Nonlinear Dynamics; D010599:Pharmacokinetics; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D012107:Research Design